These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17464992)

  • 21. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Lin XH; Si CW; Yu YY; Li J; Chen XY; Ren XM; Liu P; Zhang SL; Kang XP
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):898-901. PubMed ID: 17196132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data.
    Yoon EL; Yim HJ; Lee HJ; Lee YS; Kim JH; Jung ES; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Clin Gastroenterol; 2011; 45(10):893-9. PubMed ID: 21617542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.
    Kim JH; Yim HJ; Jung ES; Jung YK; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Viral Hepat; 2011 Apr; 18(4):287-93. PubMed ID: 20367793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.
    Lim SG; Leung N; Hann HW; Lau GK; Trepo C; Mommeja-Marin H; Moxham C; Sorbel J; Snow A; Blum MR; Rousseau F; Marcellin P
    Aliment Pharmacol Ther; 2008 Jun; 27(12):1282-92. PubMed ID: 18363895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
    Zeng M; Mao Y; Yao G; Wang H; Hou J; Wang Y; Ji BN; Chang CN; Barker KF
    Hepatology; 2006 Jul; 44(1):108-16. PubMed ID: 16799983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
    Gilson RJ; Chopra KB; Newell AM; Murray-Lyon IM; Nelson MR; Rice SJ; Tedder RS; Toole J; Jaffe HS; Weller IV
    J Viral Hepat; 1999 Sep; 6(5):387-95. PubMed ID: 10607255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B].
    Koh KH; Kang CJ; Kim DH; Choi YW; Kim MJ; Cheong JY; Cho SW
    Korean J Gastroenterol; 2008 Nov; 52(5):325-8. PubMed ID: 19077481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clevudine for hepatitis B.
    Anderson DL
    Drugs Today (Barc); 2009 May; 45(5):331-50. PubMed ID: 19584963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.